A Treatment Option for ROS1+ NSCLC

Wednesday January 17, 2024
12:15 - 12:45 pm ET

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, representing up to 84% of diagnoses. ROS1 fusions are rare and occur in about 1-2% of patients with NSCLC. Patients with tumors that are ROS1-positive tend to be younger than the average patient with lung cancer, more often female and may have little to no smoking history. Per US treatment guidelines, ROS1 targeted agents are preferred in patients with a tumor harboring this alteration.

Join a leading oncology expert to discuss recent clinical data for the application of an emerging treatment for ROS1-positive NSCLC.

Scan or click the QR code below to register!

Presented by:
Samer Kasbari, MD, MS
Hematologist/Oncologist, Principal Investigator, Sub-Investigator Southeastern Medical Oncology Center NC

Sponsored by:
Bristol Myers Squibb®